InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the detailed record of transactions filed by Berkenblit Anna, Vice-Présidente Senior et Directrice Médicale. Officer active across 1 company, notably ImmunoGen, Inc.. Cumulatively, 5 filings have been logged. History available since 30 June 2021. The latest transaction was disclosed on 30 June 2023 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Berkenblit Anna
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报5 总计
3,264 股@ US$4.0519.7% 占其流量Common StockSEC:0001415889-23-010828:0
436 股@ US$3.922.6% 占其流量Common StockSEC:0001415889-23-000108:0
3,073 股@ US$3.82518.2% 占其流量Common StockSEC:0001415889-22-007332:0
1,761 股@ US$5.6020.1% 占其流量Common StockSEC:0001179110-22-000106:0
2,062 股@ US$5.5222.2% 占其流量Common StockSEC:0001179110-21-007318:0
5 条申报中的 5 条
About Berkenblit Anna
Anna Berkenblit is the Senior Vice President and Chief Medical Officer at ImmunoGen, Inc. She oversees the medical and scientific activities of the company, ensuring alignment with strategic objectives. Her expertise is crucial for the development of new treatments.
